{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T18:20:09Z","timestamp":1766600409867},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s10875-013-9885-2","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T05:53:45Z","timestamp":1364277225000},"page":"947-953","source":"Crossref","is-referenced-by-count":29,"title":["Serum Levels of Calreticulin in Correlation with Disease Activity in Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"33","author":[{"given":"Min","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"key":"9885_CR1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319.","journal-title":"N Engl J Med"},{"key":"9885_CR2","first-page":"1037","volume":"72","author":"JA Rindfleisch","year":"2005","unstructured":"Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72:1037\u201347.","journal-title":"Am Fam Physician"},{"issue":"Suppl 2","key":"9885_CR3","first-page":"ii94","volume":"62","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis. 2003;62 Suppl 2:ii94\u20136.","journal-title":"Ann Rheum Dis"},{"key":"9885_CR4","first-page":"3","volume":"66","author":"P Emery","year":"2002","unstructured":"Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol Suppl. 2002;66:3\u20138.","journal-title":"J Rheumatol Suppl"},{"key":"9885_CR5","doi-asserted-by":"crossref","first-page":"S09","DOI":"10.18553\/jmcp.2011.17.s9-b.S09","volume":"17","author":"K Farheen","year":"2011","unstructured":"Farheen K, Agarwal SK. Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manag Care Pharm. 2011;17:S09\u201313.","journal-title":"J Manag Care Pharm"},{"key":"9885_CR6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138.","journal-title":"Arthritis Rheum"},{"key":"9885_CR7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10165-010-0328-0","volume":"20","author":"N Nishimoto","year":"2010","unstructured":"Nishimoto N, Takagi N. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol. 2010;20:539\u201347.","journal-title":"Mod Rheumatol"},{"key":"9885_CR8","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23:S93\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"9885_CR9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/ard.2006.063834","volume":"66","author":"T Matsui","year":"2007","unstructured":"Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66:1221\u20136.","journal-title":"Ann Rheum Dis"},{"key":"9885_CR10","first-page":"1095","volume":"31","author":"PH Dessein","year":"2004","unstructured":"Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol. 2004;31:1095\u20137.","journal-title":"J Rheumatol"},{"key":"9885_CR11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3899\/jrheum.080796","volume":"36","author":"X Liu","year":"2009","unstructured":"Liu X, Jia R, Zhao J, Li Z. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. J Rheumatol. 2009;36:1136\u201342.","journal-title":"J Rheumatol"},{"key":"9885_CR12","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00296-011-1912-0","volume":"32","author":"B Zamani","year":"2012","unstructured":"Zamani B, Jamali R, Jamali A. Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int. 2012;32:1967\u201375.","journal-title":"Rheumatol Int"},{"key":"9885_CR13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10067-011-1737-y","volume":"30","author":"SA Metawi","year":"2011","unstructured":"Metawi SA, Abbas D, Kamal MM, Ibrahim MK. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol. 2011;30:1201\u20137.","journal-title":"Clin Rheumatol"},{"key":"9885_CR14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1365-3083.1999.00542.x","volume":"49","author":"P Eggleton","year":"1999","unstructured":"Eggleton P, Llewellyn DH. Pathophysiological roles of calreticulin in autoimmune disease. Scand J Immunol. 1999;49:466\u201373.","journal-title":"Scand J Immunol"},{"key":"9885_CR15","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/ar2644","volume":"11","author":"V Go\u00ebb","year":"2009","unstructured":"Go\u00ebb V, Thomas-L\u2019Otellier M, Daveau R, Charlionet R, Fardellone P, Le Lo\u00ebt X, et al. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther. 2009;11:R38.","journal-title":"Arthritis Res Ther"},{"key":"9885_CR16","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.4049\/jimmunol.1000536","volume":"185","author":"C Hong","year":"2010","unstructured":"Hong C, Qiu X, Li Y, Huang Q, Zhong Z, Zhang Y, et al. Functional analysis of recombinant calreticulin fragment 39\u2013272: implications for immunobiological activities of calreticulin in health and disease. J Immunol. 2010;185:4561\u20139.","journal-title":"J Immunol"},{"key":"9885_CR17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0962-8924(01)01926-2","volume":"11","author":"S Johnson","year":"2001","unstructured":"Johnson S, Michalak M, Opas M, Eggleton P. The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol. 2001;11:122\u20139.","journal-title":"Trends Cell Biol"},{"key":"9885_CR18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2010.05745.x","volume":"1209","author":"J Holoshitz","year":"2010","unstructured":"Holoshitz J, De Almeida DE, Ling S. A role for calreticulin in the pathogenesis of rheumatoid arthritis. Ann N Y Acad Sci. 2010;1209:91\u20138.","journal-title":"Ann N Y Acad Sci"},{"key":"9885_CR19","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.4049\/jimmunol.179.9.6359","volume":"179","author":"S Ling","year":"2007","unstructured":"Ling S, Pi X, Holoshitz J. The rheumatoid arthritis shared epitope triggers innate immune signaling via cell surface calreticulin. J Immunol. 2007;179:6359\u201367.","journal-title":"J Immunol"},{"key":"9885_CR20","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/art.27602","volume":"62","author":"JM Tarr","year":"2010","unstructured":"Tarr JM, Winyard PG, Ryan B, Harries LW, Haigh R, Viner N, et al. Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells. Arthritis Rheum. 2010;62:2919\u201329.","journal-title":"Arthritis Rheum"},{"key":"9885_CR21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jmb.2010.06.064","volume":"401","author":"JM Tarr","year":"2010","unstructured":"Tarr JM, Young PJ, Morse R, Shaw DJ, Haigh R, Petrov PG, et al. A mechanism of release of calreticulin from cells during apoptosis. J Mol Biol. 2010;401:799\u2013812.","journal-title":"J Mol Biol"},{"key":"9885_CR22","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/art.24035","volume":"58","author":"RM Thurlings","year":"2008","unstructured":"Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of retreatment in initial nonresponders versus initial responders. Arthritis Rheum. 2008;58:3657\u201364.","journal-title":"Arthritis Rheum"},{"key":"9885_CR23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3899\/jrheum.111027","volume":"39","author":"LF Rocha da","year":"2012","unstructured":"da Rocha LF, Jr D\u00c2L, Dantas AT, Mariz HA, Pitta Ida R, Galdino SL, et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol. 2012;39:1320\u20135.","journal-title":"J Rheumatol"},{"key":"9885_CR24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-006-0275-5","volume":"26","author":"S Agrawal","year":"2007","unstructured":"Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 2007;26:201\u20134.","journal-title":"Clin Rheumatol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-013-9885-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-013-9885-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-013-9885-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T11:13:10Z","timestamp":1644664390000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-013-9885-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["9885"],"URL":"https:\/\/doi.org\/10.1007\/s10875-013-9885-2","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}